Science That Can’t Be Silenced | Join our Exclusive Members Only Community | The Perks & Access Are Insane | Free Trial👇🏼(limited time)
May 14 • 13 tweets • 4 min read
Everyone calls retatrutide "the Ozempic and tirzepatide killer" with triple agonist power.
But if you look at the data we have right now, tirzepatide might be the smarter choice.
Tirzepatide, explained: (1/13)
Reta's most cited number is the 24.2% weight loss, from a Phase 2 trial of just 338 people over 48 weeks.
It now has one Phase 3 result (TRIUMPH-4: 28.7%), but that was 445 knee osteoarthritis patients, not a general obesity population.
Tirze's 22.5% came from 2,500+ people.
May 11 • 12 tweets • 3 min read
Retatrutide is positioned to be the best-selling drug ever.
In trials, it led to 24% weight loss over 48 weeks and reversed fatty liver in 93% of patients. Eli Lilly is still working through Phase 3.
But what makes it better than semaglutide and tirzepatide? (1/12)
We are seeing three generations of GLP-1 drugs.
- Semaglutide (Ozempic) targets one receptor
- Tirzepatide (Mounjaro) targets two
- Retatrutide hits three
Every new version has essentially doubled the weight loss results of the previous one.
May 7 • 9 tweets • 2 min read
Semax, explained: (1/9)
Since 2011, Semax has been on the Russian list of essential drugs. If you have a stroke in Moscow, they put this up your nose in the ambulance.
It's a frontline neuroprotective tool and a standard part of their medical care, not some niche biohack.
Apr 6 • 11 tweets • 3 min read
Every weight loss drug does one thing: make you eat less.
Retatrutide does that, and makes you burn more calories at rest. No drug has ever done both.
